Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 6Lymphoma 6Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Carcinoma, Ovarian Epithelial 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × 7-hydroxystaurosporine × Clear all
NCT00098956 2018-07-23

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡